{"title": "Pure Omega-3 prescription drug markedly reduces first, repeat and total CV events", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/heart_disease.xml", "value": "Pure Omega-3 prescription drug markedly reduces first, repeat and total CV events"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2019/03/190318113818.htm"}], "link": "https://www.sciencedaily.com/releases/2019/03/190318113818.htm", "summary": "Taking a high dose of icosapent ethyl -- a pure and stable prescription form of the omega-3 fatty acid known as EPA -- significantly reduces the occurrence of first, subsequent and total ischemic events, including heart attacks, strokes and related deaths, among people at high cardiovascular risk despite already being on statin therapy, according to new research.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/heart_disease.xml", "value": "Taking a high dose of icosapent ethyl -- a pure and stable prescription form of the omega-3 fatty acid known as EPA -- significantly reduces the occurrence of first, subsequent and total ischemic events, including heart attacks, strokes and related deaths, among people at high cardiovascular risk despite already being on statin therapy, according to new research."}, "published": "Mon, 18 Mar 2019 11:38:18 EDT", "published_parsed": [2019, 3, 18, 15, 38, 18, 0, 77, 0], "id": "https://www.sciencedaily.com/releases/2019/03/190318113818.htm", "guidislink": false}